Idorsia’s Fabry flop puts focus on gene therapies
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Bluebird split looks premature
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Finding the next Prevail
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Bristol bets on cytokines again
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
Amicus muscles in on Pompe gene therapy chase
As data on Amicus Therapeutics' clinical-stage Pompe disease candidate roll in, the group locks up preclinical gene therapy assets.
Gene therapy deal-making shows no signs of stopping
Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.
June rush drives near-record quarter for biotech flotations
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.
